Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2004 Jan;65(1):79–89. doi: 10.1016/S0011-393X(04)90007-0

Effects of rosiglitazone treatment on the pentose phosphate pathway and glutathione-dependent enzymes in liver and kidney of rats fed a high-fat diet

Esen Akbay 1, Nuriye Nuray Ulusu 2, Füsun Töröner 3, Göksun Ayvaz 3, Ferit Taneri 4, Müjde Aktürk 3, Metin Arslan 3, Çimen Karasu 5,∗
PMCID: PMC4052959  PMID: 24936106

Abstract

Background: Animals fed high-fat diets have been shown to develop hyperglycemia, insulin resistance, hyperlipidemia, and moderate obesity, which resemble the human metabolic syndrome. Obesity, the metabolic syndrome, and some thiazolidinediones, which act as insulin sensitizers, may increase oxidative stress, and/or influence the levels of cellular reducing equivalents and homeostasis.

Objective: This study investigated the effects of a high-fat diet, rosiglitazone, or a high-fat diet plus rosiglitazone on metabolic syndrome parameters and crucial liver and kidney enzyme activities in rats.

Methods: Male Wistar rats were assigned to 4 groups (n = 6 per group): (1) the fat (F) group was fed a rodent diet comprising 45 kcal% fat, (2) the rosiglitazone (R) group was fed a standard rat chow comprising 4.97 kcal% fat plus rosiglitazone (3 mg/kg.d), (3) the fat + rosiglitazone (FR) group was fed a rodent diet comprising 45 kcal% fat (as lard, product D12451) plus rosiglitazone (3 mg/kg.d), and (4) the control (C) group was fed a standard rat chow comprising 4.97 kcal% fat. Animals were housed for 4 weeks, at which time the liver and kidney were isolated for spectrophotometric determination of enzyme activities. Body weight was measured before treatment (baseline) and then weekly throughout the study. Adiposity was measured at the end of the 4 weeks.

Results: The activities of glucose-6-phosphate dehydrogenase (G6PD), 6-phosphogluconate dehydrogenase (6-PGD), glutathione reductase (GR), and glutathione-S-transferase (GST) were significantly reduced in the livers of groups F, R, and FR compared with group C (all P < 0.05). Kidney G6PD, 6-PGD, and GR were found to be significantly lower in group R compared with the other groups (all P < 0.05). Kidney GST was similar in all groups. Plasma glucose, triglyceride, and insulin concentrations were significantly higher than in group F versus the other groups (all P < 0.05). Adiposity was increased in groups F and FR compared with groups C and R (all P < 0.05). Serum cholesterol concentrations were similar in all groups.

Conclusions: In this study, high-fat diet in rats decreased the enzyme activities responsible for pentose phosphate pathway and glutathione-dependent metabolism in liver but not in kidney. Similarly, these enzyme activities were inhibited with rosiglitazone treatment alone in both organs.

Keywords: rosiglitazone, pentose phosphate pathway, glutathione-dependent metabolism, metabolic syndrome, high-fat diet, rat, obesity

Full Text

The Full Text of this article is available as a PDF (597.3 KB).

References

  • 1.Trevisan M, Browne R, Ram M. Correlates of markers of oxidative status in the general population. Am J Epidemiol. 2001;154:348–356. doi: 10.1093/aje/154.4.348. [DOI] [PubMed] [Google Scholar]
  • 2.Sevanian A, Hochstein P. Mechanisms and consequences of lipid peroxidation in biological systems. Annu Rev Nutr. 1985;5:365–390. doi: 10.1146/annurev.nu.05.070185.002053. [DOI] [PubMed] [Google Scholar]
  • 3.Basaga H.S. Biochemical aspects of free radicals. Biochem Cell Biol. 1990;68:989–998. doi: 10.1139/o90-146. [DOI] [PubMed] [Google Scholar]
  • 4.Hayes J.D, McLellan L.I. Glutathione and glutathione-dependent enzymes represent a coordinately regulated defence against oxidative stress. Free Radic Res. 1999;31:273–300. doi: 10.1080/10715769900300851. [DOI] [PubMed] [Google Scholar]
  • 5.Deneke S.M, Fanburg B.L. Regulation of cellular glutathione. Am J Physiol. 1989;257:L163–L173. doi: 10.1152/ajplung.1989.257.4.L163. [DOI] [PubMed] [Google Scholar]
  • 6.Wood T. Physiological functions of the pentose phosphate pathway. Cell Biochem Funct. 1986;4:241–247. doi: 10.1002/cbf.290040403. [DOI] [PubMed] [Google Scholar]
  • 7.Tallman D.L, Taylor C.G. Effects of dietary fat and zinc on adiposity, serum leptin and adipose fatty acid composition in C57BL/6J mice. J Nutr Biochem. 2003;14:17–23. doi: 10.1016/s0955-2863(02)00228-0. [DOI] [PubMed] [Google Scholar]
  • 8.Chen L.C, Boissonneault G, Hayek M.G, Chow C.K. Dietary fat effects on hepatic lipid peroxidation and enzymes of H202 metabolism and NADPH generation. Lipids. 1993;28:657–662. doi: 10.1007/BF02536062. [DOI] [PubMed] [Google Scholar]
  • 9.Watson A.M, Poloyac S.M, Howard G, Blouin R.A. Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse. Drug Metab Dispos. 1999;27:695–700. [PubMed] [Google Scholar]
  • 10.Saltiel A.R, Olefsky J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45:1661–1669. doi: 10.2337/diab.45.12.1661. [DOI] [PubMed] [Google Scholar]
  • 11.Willson T.M, Lambert M.H, Kliewer S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem. 2001;70:341–367. doi: 10.1146/annurev.biochem.70.1.341. [DOI] [PubMed] [Google Scholar]
  • 12.Malinowski J.M, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: A critical review. Clin Ther. 2000;22:1151–1168. doi: 10.1016/s0149-2918(00)83060-x. [published correction appears in Clin Ther. 2001;23:309] [DOI] [PubMed] [Google Scholar]
  • 13.Chen L.C, Tatum V, Glauert H.P, Chow C.K. Peroxisome proliferator perfluorodecanoic acid alters glutathione and related enzymes. J Biochem Mol Toxicol. 2001;15:107–113. doi: 10.1002/jbt.6. [DOI] [PubMed] [Google Scholar]
  • 14.O'Brien M.L, Twaroski T.P, Cunningham M.L. Effects of peroxisome proliferators on antioxidant enzymes and antioxidant vitamins in rats and hamsters. Toxicol Sci. 2001;60:271–278. doi: 10.1093/toxsci/60.2.271. [DOI] [PubMed] [Google Scholar]
  • 15.Narayanan P.K, Hart T, Elcock F. Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: A flow cytometric assessment. Cytometry. 2003;52A:28–35. doi: 10.1002/cyto.a.10011. [DOI] [PubMed] [Google Scholar]
  • 16.Lennon A.M, Ramauge M, Dessouroux A, Pierre M. MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-Delta(12–14)-prostaglandin J(2) and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-independent mechanisms involving reactive oxygenated species. J Biol Chem. 2002;277:29681–29685. doi: 10.1074/jbc.M201517200. [DOI] [PubMed] [Google Scholar]
  • 17.Ulusu N.N, Kus M.S, Acan N.L, Tezcan E.F. A rapid method for the purification of glucose-6-phosphate dehydrogenase from bovine lens. Int J Biochem Cell Biol. 1999;31:787–796. doi: 10.1016/s1357-2725(99)00019-9. [DOI] [PubMed] [Google Scholar]
  • 18.Pearse B.M, Rosemeyer M.A. 6-Phosphogluconate dehydrogenase from human erythrocytes. Methods Enzymol. 1975;41:220–226. doi: 10.1016/s0076-6879(75)41051-5. [DOI] [PubMed] [Google Scholar]
  • 19.Habig W.H, Pabst M.J, Jakoby W.B. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem. 1974;249:7130–7139. [PubMed] [Google Scholar]
  • 20.Acan N.L, Tezcan E.F. Sheep brain glutathione reductase: Purification and general properties. FEBS Lett. 1989;250:72–74. doi: 10.1016/0014-5793(89)80687-8. [DOI] [PubMed] [Google Scholar]
  • 21.Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  • 22.Shapiro R, Nuss M.E, Kaszubska W. Poster presented at: 83rd Annual Meeting of the Endocrine Society. 2001. Effects of treatment of C57BL/6J mice fed high fat vs. low fat diets with metformin or rosiglitazone on adiposity, food intake, hyperglycemia and insulin resistance. Denver, Colo. [Google Scholar]
  • 23.Pickavance L.C, Tadayyon M, Widdowson P.S. Therapeutic index for rosiglitazone in dietary obese rats: Separation of efficacy and haemodilution. Br J Pharmacol. 1999;128:1570–1576. doi: 10.1038/sj.bjp.0702932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Carey D.G, Galloway G, Dodrell D. Rosiglitazone reduces hepatic fat and increases subcutaneous but not intra-abdominal fat depots. Diabetologia. 2000;43(Suppl 1):A181. Abstract. [Google Scholar]
  • 25.Ayala A, Fabregat I, Machado A. The role of NADPH in the regulation of glucose-6- phosphate and 6-phosphogluconate dehydrogenases in rat adipose tissue. Mol Cell Biochem. 1991;105:1–5. doi: 10.1007/BF00230368. [DOI] [PubMed] [Google Scholar]
  • 26.Ashby J, Brady A, Elcombe C.R. Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum Exp Toxicol. 1994;13(Suppl 2):S1–S117. doi: 10.1177/096032719401300201. [DOI] [PubMed] [Google Scholar]
  • 27.Reddy J.K, Warren J.R, Reddy M.K, Lalwani N.D. Hepatic and renal effects of peroxisome proliferators: Biological implications. Ann NY Acad Sci. 1982;386:81–110. doi: 10.1111/j.1749-6632.1982.tb21409.x. [DOI] [PubMed] [Google Scholar]
  • 28.Tettey J.N, Maggs J.L, Rapeport W.G. Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem Res Toxicol. 2001;14:965–974. doi: 10.1021/tx0001981. [DOI] [PubMed] [Google Scholar]
  • 29.Lloyd S, Hayden M.J, Sakai Y. Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors. Chem Biol Interact. 2002;142:57–71. doi: 10.1016/s0009-2797(02)00054-6. [DOI] [PubMed] [Google Scholar]
  • 30.Teruel T, Hernandez R, Benito M, Lorenzo M. Rosiglitazone and retinoic acid induce uncoupling protein-1 (UCP-1) in a p38 mitogen-activated protein kinase-dependent manner in fetal primary brown adipocytes. J Biol Chem. 2003;278:263–269. doi: 10.1074/jbc.M207200200. [DOI] [PubMed] [Google Scholar]
  • 31.Lawrence R.A, Parkhill L.K, Burk R.F. Hepatic cytosolic non selenium-dependent glutathione peroxidase activity: Its nature and the effect of selenium deficiency. J Nutr. 1978;108:981–987. doi: 10.1093/jn/108.6.981. [DOI] [PubMed] [Google Scholar]
  • 32.Ashida H, Nakai R, Kanazawa K, Danno G. Xenobiotic tolerance of primary cultured hepatocytes in rats fed a high-fat or high-protein diet. J Nutr Sci Vitaminol (Tokyo) 1998;44:89–102. doi: 10.3177/jnsv.44.89. [DOI] [PubMed] [Google Scholar]
  • 33.York J.L, Wolff G.L. Vol. 205. 1994. Glutathione S-transferase activity and isoenzyme concentrations in obese AVY/a and lean a/a mice; pp. 186–189. (Proc Soc Exp Biol Med). [DOI] [PubMed] [Google Scholar]
  • 34.Barnett C.R, Abbott R.A, Bailey C.J. Cytochrome P-450-dependent mixed-function oxidase and glutathione S-transferase activities in spontaneous obesity-diabetes. Biochem Pharmacol. 1992;43:1868–1871. doi: 10.1016/0006-2952(92)90724-w. [DOI] [PubMed] [Google Scholar]
  • 35.Salazar D.E, Sorge C.L, Jordan S.W, Corcoran G.B. Obesity decreases hepatic glutathione concentrations and markedly potentiates allyl alcohol-induced periportal necrosis in the overfed rat. Int J Obes Relat Metab Disord. 1994;18:25–33. [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES